Sort
16,300 grants matching “fatty liver disease”
Software for predicting liver injury from biologics drug candidates using data from a human liver microphysiology system
$834,404Kyunghee Yang · Simulations Plus, Inc. · R44 · FY2023 · TR
Clinical Research Network in Non Alcoholic Steatohepatitis
$834,264Kris Kowdley · Benaroya Research Inst At Virginia Mason · U01 · FY2008 · DK
Molecular and Clinical Studies of Insulin Resistance
$833,192Rebecca Brown · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
Adverse metabolic effects of dietary sugar _ Ad libitum vs energy-balanced diets
$832,999Peter J Havel · University Of California At Davis · R01 · FY2016 · HL
Investigator Development Core
$832,586Donna D Spruijt-Metz · Children'S Hospital Of Los Angeles · P50 · FY2025 · MD
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)
$832,002Manal M Hassan · University Of Tx Md Anderson Can Ctr · R01 · FY2015 · CA
Fat and Iron-Corrected Quantitative MRI T1 Mapping for Evaluation of Chronic Liver Disease
$830,401Li Feng · New York University School Of Medicine · R01 · FY2025 · DK
Breast Cancer Survivors Cardiovascular Risks: Treatment and Behavioral Influences
$829,667Janice K Kiecolt-Glaser · Ohio State University · R01 · FY2014 · CA
YAP signaling in the pathogenesis of NAFLD in people living with HIV
$829,042Raymond T Chung · Massachusetts General Hospital · R01 · FY2023 · DK
Toward Diagnostics and Therapies of Molecular Subcategories of CAD
$828,928Johan M Bjorkegren · Icahn School Of Medicine At Mount Sinai · R01 · FY2015 · HL
Liver Cancer Disparities in Alaska Native and American Indian People
$828,416George Ioannou · University Of Washington · P20 · FY2023 · CA
Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy
$827,898Yaron Rotman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
MOTS-C, APOE, and Alzheimer's disease
$827,764Christian J Pike · University Of Southern California · R01 · FY2024 · AG
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
$827,529Inga Peter · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · HG
Epigenetics of Development
$826,813Brant Weinstein · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2020 · HD
Physiologic Consequence of Genetic Variation
$825,938Richard M Watanabe · University Of Southern California · R01 · FY2015 · DK
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
$825,656Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Molecular signatures for liver cancer diagnosis and treatment stratification
$825,166Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
$824,847Inga Peter · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · HG
MASLD protection by STAT5-regulated transcription factors
$824,655Rhonda D. Kineman · University Of Illinois At Chicago · R01 · FY2025 · DK
Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism
$824,518Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2012 · AA
Dietary treatment of Glucose Transporter Type 1 Deficiency (G1D)
$824,012Juan M. Pascual · Ut Southwestern Medical Center · R01 · FY2016 · NS
Imaging of Aortic Atherosclerosis and Inflammation in the Metabolic Syndrome
$823,860Warren J Manning · Beth Israel Deaconess Medical Center · R01 · FY2009 · HL
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
$823,854Jay W Heinecke · University Of Washington · R01 · FY2023 · HL
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
$823,854Jay W Heinecke · University Of Washington · R01 · FY2024 · HL